case_images: PMC11757265_01
case_images: The results of abdominal CT scan of patients with preoperative and postoperative recurrence. (A-C) Preoperative abdominal CT revealed that an exogenous mass with a diameter of approximately 16 cm can be seen in the fourth segment of the liver, protruding toward the right diaphragm and invading the diaphragm, and the tumor surface was ruptured. (D-F) Postoperative abdominal CT revealed that two areas of low enhancement in the surgical region, with clear boundaries. The larger region was approximately 15 cm, and contained multiple necrotic regions.
case_images: fmed-11-1470419-g001.jpg
case_images: PMC11757265_01_fmed-11-1470419-g001.jpg
case_images: fig1
case_images: A computed tomography (CT) enhancement scan revealed one instance of intrahepatic enhancement with mixed density and a massive, enhanced shadow located mainly outside the liver (Figures 1A-C). The larger region was approximately 15 cm, and contained multiple necrotic regions (Figures 1D-F).
case_images: Pathological findings. (A) The cholangiocarcinoma component (HE x200). (B) The sarcoma component consists mainly of fusiform cells (HE x200). (C) Border area between cholangiocarcinoma and sarcomatoid components (HE x200). (D) CK7 was positive in the tumor (IHC x200). (E) Vimentin was positive in the tumor (IHC x200). (F) The expression of Ki-67 in the tumor cells was approximately 45% (IHC x200).
case_images: fmed-11-1470419-g002.jpg
case_images: PMC11757265_01_fmed-11-1470419-g002.jpg
case_images: fig2
case_images: Immunohistochemical analyses revealed that the tumor cells were negative for AFP, HepPar-1, CEA, GPC-3, CK19, CK20, Syn, CgA, and CD56 but positive for CK7, Vimentin, and Ki-67, with a Ki-67 expression level of approximately 45% (Figure 2).